Cargando…

10-Year Evaluation of Adherence and Satisfaction with Information about Tolvaptan in ADPKD: A Single-Center Pilot Study

PURPOSE: Tolvaptan is the only approved drug for the treatment of autosomal dominant polycystic kidney disease (ADPKD) and causes significant polyuria with secondary polydipsia. Up to now, there is no study that examines tolvaptan adherence and satisfaction with information received about tolvaptan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schirutschke, Holger, Gross, Peter, Paliege, Alexander, Hugo, Christian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427080/ https://www.ncbi.nlm.nih.gov/pubmed/34511889 http://dx.doi.org/10.2147/PPA.S325738

Ejemplares similares

Tolvaptan in ADPKD Patients With Very Low Kidney Function
por: Torres, Vicente E., et al.
Publicado: (2021)

Effect of Tolvaptan Treatment on Acid−Base Homeostasis in ADPKD Patients
por: Bargagli, Matteo, et al.
Publicado: (2021)

Long-Term Outcomes of Longitudinal Efficacy Study With Tolvaptan in ADPKD
por: Higashihara, Eiji, et al.
Publicado: (2021)

Potential effect of tolvaptan on polycystic liver disease for patients with ADPKD meeting the Japanese criteria of tolvaptan use
por: Mizuno, Hiroki, et al.
Publicado: (2022)

Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD
por: Zhou, Xiaolei, et al.
Publicado: (2022)

Effects of Tolvaptan on Oxidative Stress in ADPKD: A Molecular Biological Approach
por: Rigato, Matteo, et al.
Publicado: (2022)

A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD
por: Perrone, Ronald D., et al.
Publicado: (2020)

Per-Treatment Post Hoc Analysis of Clinical Trial Outcomes With Tolvaptan in ADPKD
por: Mallett, Andrew J., et al.
Publicado: (2021)

Urinary Aquaporin 2 as a Potential Indicator Predicting Tolvaptan Response in Patients With ADPKD
por: Makabe, Shiho, et al.
Publicado: (2021)

Author’s Reply to Correspondence: “Effect of Tolvaptan Treatment on Acid−Base Homeostasis in ADPKD Patients”
por: Heida, Judith E., et al.
Publicado: (2021)

Clinical Utility and Tolerability of Tolvaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
por: Raina, Rupesh, et al.
Publicado: (2022)

The Effect of Dietary Intervention on Autosomal-Dominant Polycystic Kidney Disease (ADPKD) Patients on Tolvaptan and Their Quality of Life
por: Tarabzuni, Ola
Publicado: (2022)

Interaction Between Determinants Governing Urine Volume in Patients With ADPKD on Tolvaptan and its Impact on Quality of Life
por: Todorova, Polina, et al.
Publicado: (2023)

Outcomes from the Northeast England cohort of autosomal dominant polycystic kidney disease (ADPKD) patients on tolvaptan
por: Gkekas, Eleftherios, et al.
Publicado: (2022)

Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment
por: Barnawi, Rashid A, et al.
Publicado: (2018)

Case report: tolvaptan-associated creatine kinase elevation in two patients with autosomal dominant polycystic kidney disease (ADPKD)
por: Agraz-Pamplona, I., et al.
Publicado: (2020)

Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report
por: Pellegrino, Angela Maria, et al.
Publicado: (2019)

Pulmonary Embolism in a Patient With ADPKD Treated With Tolvaptan: From the Clinical Experience to the Analysis of the Food and Drug Administration Adverse Event Reporting System Registry
por: Aiello, Valeria, et al.
Publicado: (2021)

Heterogeneous Cardiovascular Profiles in CKD: ADPKD Versus non-ADPKD
por: Au, Eric H.K., et al.
Publicado: (2022)

Tolvaptan
por: Rangarajan, Bharath, et al.
Publicado: (2014)

Modelling the long-term benefits of tolvaptan therapy on renal function decline in autosomal dominant polycystic kidney disease: an exploratory analysis using the ADPKD outcomes model
por: Bennett, Hayley, et al.
Publicado: (2019)

Antenatally Diagnosed ADPKD
por: Aldridge, Melanie, et al.
Publicado: (2018)

Intrafamilial Variability of ADPKD
por: Lanktree, Matthew B., et al.
Publicado: (2019)

Simultaneous laparoscopic nephrectomy in ADPKD
por: Baishya, Ramen Kumar, et al.
Publicado: (2010)

Polycystins, ADPKD, and Cardiovascular Disease
por: Kuo, Ivana Y., et al.
Publicado: (2019)

Defining Cardiac Dysfunction in ADPKD
por: Kuo, Ivana Y.
Publicado: (2023)

Cardiovascular Manifestations and Management in ADPKD
por: Sagar, Priyanka S., et al.
Publicado: (2023)

Predicting the Risk of Progression in Indian ADPKD Cohort using PROPKD Score – A Single-Center Retrospective Study
por: Singh, Shivendra, et al.
Publicado: (2023)

Tolvaptan- and Tolvaptan-Metabolite-Responsive T Cells in Patients with Drug-Induced Liver Injury
por: Gibson, Andrew, et al.
Publicado: (2020)

Comparison of tolvaptan treatment between patients with the SIADH and congestive heart failure: a single-center experience
por: Park, Gun Ha, et al.
Publicado: (2018)

Tolvaptan in the Management of Acute Euvolemic Hyponatremia After Transsphenoidal Surgery: A Retrospective Single-Center Analysis
por: Indirli, Rita, et al.
Publicado: (2021)

Estimating Growth Rate by a Single Measurement of Kidney Volume in ADPKD
por: Narita, Ichiei
Publicado: (2020)

Evaluation of advanced imaging biomarkers at kidney failure in patients with ADPKD: a pilot study
por: Wigerinck, Stijn, et al.
Publicado: (2023)

The importance of quantifying genetic heterogeneity in ADPKD
por: Chapman, Arlene B.
Publicado: (2014)

Renal Transcatheter Arterial Embolization for ADPKD
por: Oda, Yasuhiro, et al.
Publicado: (2020)

Renal Volume in ADPKD Patient Evaluation
por: Galliani, M., et al.
Publicado: (2020)

The imaging of total kidney volume in ADPKD
por: Cavoli, Gioacchino Li, et al.
Publicado: (2020)

The Impact of COVID-19 on Patients With ADPKD
por: Kutky, Meherzad, et al.
Publicado: (2021)

Germline Mutations for Kidney Volume in ADPKD
por: Kataoka, Hiroshi, et al.
Publicado: (2021)

Imaging Biomarkers in Young Patients With ADPKD
por: Yang, Xinyi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4698qjn7bbk15l6vmbjti79upf